LENZ Therapeutics Inc (LENZ)

Currency in USD
29.96
+0.19(+0.64%)
Closed·
After Hours
30.25+0.29(+0.97%)
·
LENZ Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Fair Value
Day's Range
29.0031.59
52 wk Range
16.5438.93
Key Statistics
Prev. Close
29.77
Open
30.01
Day's Range
29-31.59
52 wk Range
16.54-38.93
Volume
1.57M
Average Volume (3m)
294.2K
1-Year Change
24.73%
Book Value / Share
7.33
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LENZ Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
49.63
Upside
+65.64%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

LENZ Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

LENZ Therapeutics Inc Company Profile

LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

LENZ Therapeutics Inc Earnings Call Summary for Q1/2025

  • Q1 2025: $194.1M cash, $0.53 net loss/share. LNZ100 PDUFA date: Aug 8, 2025. Stock at $25.34, down 2.12%.
  • Presbyopia market potential: $3B+, 128M Americans affected. LENZ expanding sales force, 40%+ offers accepted.
  • Q1 expenses up: Operating $16.9M (+11% QoQ), SG&A $11.3M (2x YoY). Net cash burn: $15M.
  • LNZ100 commercial launch by early 2026. Analyst consensus: 'Strong Buy', targets $36-$60.
  • CEO confident in treatment efficacy. CCO sees product as 'category of one'. Aiming for cash flow positive.
Last Updated: 07/05/2025, 22:36
Read Full Transcript

Compare LENZ to Peers and Sector

Metrics to compare
LENZ
Peers
Sector
Relationship
P/E Ratio
−16.3x−0.3x−0.5x
PEG Ratio
−0.210.000.00
Price/Book
4.1x2.2x2.6x
Price / LTM Sales
170.9x1.9x3.3x
Upside (Analyst Target)
75.2%173.2%45.4%
Fair Value Upside
Unlock19.7%7.7%Unlock

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 49.63
(+65.64% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -1.90%
Dividend Yield
-
Industry Median 0.68%
Annualised payout
-
Paid unevenly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
May 07, 2025
EPS / Forecast
-0.53 / -0.47
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

LENZ Income Statement

People Also Watch

37.26
EXEL
+2.87%
7.60
REPL
+8.11%
52.13
PTCT
+0.04%
19.40
URGN
+1.78%

FAQ

What Stock Exchange Does LENZ Therapeutics Trade On?

LENZ Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for LENZ Therapeutics?

The stock symbol for LENZ Therapeutics is "LENZ."

What Is the LENZ Therapeutics Market Cap?

As of today, LENZ Therapeutics market cap is 854.52M.

What Is LENZ Therapeutics's Earnings Per Share (TTM)?

The LENZ Therapeutics EPS (TTM) is -1.90.

From a Technical Analysis Perspective, Is LENZ a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has LENZ Therapeutics Stock Split?

LENZ Therapeutics has split 1 times.

How Many Employees Does LENZ Therapeutics Have?

LENZ Therapeutics has 11 employees.

What is the current trading status of LENZ Therapeutics (LENZ)?

As of 03 Aug 2025, LENZ Therapeutics (LENZ) is trading at a price of 29.96, with a previous close of 29.77. The stock has fluctuated within a day range of 29.00 to 31.59, while its 52-week range spans from 16.54 to 38.93.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.